LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Ceftazidime Plasma Concentrations and Neurotoxicity: The Importance of Therapeutic Drug Monitoring in Patients Undergoing Different Modalities of Renal Replacement Therapy. A Grand Round.

    Robosa, Roselle S / Lau, Cindy / Stojanova, Jana / Chin, Cheau Wern / Marriott, Deborah J E

    Therapeutic drug monitoring

    2023  Volume 45, Issue 6, Page(s) 711–713

    Abstract: Abstract: Ceftazidime-avibactam (CTZ-AVM) is a novel cephalosporin/beta-lactamase inhibitor with broad-spectrum activity against multidrug-resistant Pseudomonas aeruginosa . Ceftazidime-induced neurotoxicity is a well-described adverse effect, ... ...

    Abstract Abstract: Ceftazidime-avibactam (CTZ-AVM) is a novel cephalosporin/beta-lactamase inhibitor with broad-spectrum activity against multidrug-resistant Pseudomonas aeruginosa . Ceftazidime-induced neurotoxicity is a well-described adverse effect, particularly in patients with renal insufficiency. However, appropriate dosing of ceftazidime-avibactam in patients undergoing renal replacement therapy (RRT) is sparsely investigated, and therapeutic drug monitoring to guide dosing remains lacking. Furthermore, when dose adjustment for impaired renal function is based on CTZ-AVM product information, inferior cure rates have been obtained compared with those with the standard therapy for intra-abdominal infections. Maintaining an effective dose while avoiding toxicity in these patients is challenging. Here, the authors describe the case of a critically ill patient, undergoing 2 modalities of RRT, who developed ceftazidime-induced neurotoxicity as confirmed using ceftazidime therapeutic drug monitoring. This case illustrates a therapeutic drug monitoring-based approach for guiding ceftazidime-avibactam dosing in this context and in diagnosing the cause of neurological symptoms and signs.
    MeSH term(s) Humans ; Anti-Bacterial Agents/adverse effects ; Ceftazidime/therapeutic use ; Continuous Renal Replacement Therapy ; Drug Combinations ; Drug Monitoring ; Microbial Sensitivity Tests ; Teaching Rounds
    Chemical Substances Anti-Bacterial Agents ; Ceftazidime (9M416Z9QNR) ; Drug Combinations
    Language English
    Publishing date 2023-07-03
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000001124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1503: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Clinical evaluation of SARS-CoV-2 point-of-care antibody tests.

    Robosa, Roselle S / Sandaradura, Indy / Dwyer, Dominic E / O'Sullivan, Matthew V N

    Pathology

    2020  Volume 52, Issue 7, Page(s) 783–789

    Abstract: The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on ... ...

    Abstract The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on 132 serum samples for SARS-CoV-2-specific antibody detection referred to a tertiary referral hospital laboratory in New South Wales. Multiple sera were tested from 20 confirmed or suspected COVID-19 patients with SARS-CoV-2-specific antibodies detected by immunofluorescence (IFA) or neutralisation, and 71 SARS-CoV-2 uninfected individuals. We measured the sensitivity and specificity for detection of SARS-CoV-2 IgM and IgG antibodies for each POCT in comparison to positive SARS-CoV-2-specific IFA and viral neutralisation, our current laboratory benchmark tests. All POCTs were found to have a low analytic sensitivity for SARS-CoV-2 antibodies, ranging from 27.3% to 58.2%, with a specificity between 88.3% and 100%, and a low clinical sensitivity from 45% to 65%, with a clinical specificity between 87.3% and 100%. All POCTs had an increased sensitivity when specimens were collected more than 14 days from onset of symptoms. The detection using point-of-care testing of SARS-CoV-2-specific antibodies after disease onset lagged behind IFA by a range of 0-9 days. POCTs promise the benefit of providing quick easy testing for SARS-CoV-2-specific antibodies. However, their poor sensitivity and delayed antibody detection make them unsuitable as a diagnostic or screening tool alone.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19 Serological Testing/methods ; Child ; Child, Preschool ; Female ; Humans ; Male ; Middle Aged ; Point-of-Care Testing ; Retrospective Studies ; SARS-CoV-2 ; Sensitivity and Specificity ; Young Adult
    Chemical Substances Antibodies, Viral
    Keywords covid19
    Language English
    Publishing date 2020-09-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 7085-3
    ISSN 1465-3931 ; 0031-3025
    ISSN (online) 1465-3931
    ISSN 0031-3025
    DOI 10.1016/j.pathol.2020.09.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 723: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinical evaluation of SARS-CoV-2 point-of-care antibody tests

    Robosa, Roselle S. / Sandaradura, Indy / Dwyer, Dominic E. / O'Sullivan, Matthew V.N.

    Pathology ; ISSN 0031-3025

    2020  

    Keywords Pathology and Forensic Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    DOI 10.1016/j.pathol.2020.09.002
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Clinical evaluation of SARS-CoV-2 point-of-care antibody tests

    Robosa, Roselle S / Sandaradura, Indy / Dwyer, Dominic E / O039, / Sullivan, Matthew V N

    Pathology

    Abstract: The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on ... ...

    Abstract The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on 132 serum samples for SARS-CoV-2-specific antibody detection referred to a tertiary referral hospital laboratory in New South Wales. Multiple sera were tested from 20 confirmed or suspected COVID-19 patients with SARS-CoV-2-specific antibodies detected by immunofluorescence (IFA) or neutralisation, and 71 SARS-CoV-2 uninfected individuals. We measured the sensitivity and specificity for detection of SARS-CoV-2 IgM and IgG antibodies for each POCT in comparison to positive SARS-CoV-2-specific IFA and viral neutralisation, our current laboratory benchmark tests. All POCTs were found to have a low analytic sensitivity for SARS-CoV-2 antibodies, ranging from 27.3% to 58.2%, with a specificity between 88.3% and 100%, and a low clinical sensitivity from 45% to 65%, with a clinical specificity between 87.3% and 100%. All POCTs had an increased sensitivity when specimens were collected more than 14 days from onset of symptoms. The detection using point-of-care testing of SARS-CoV-2-specific antibodies after disease onset lagged behind IFA by a range of 2-0 days. POCTs promise the benefit of providing quick easy testing for SARS-CoV-2-specific antibodies. However, their poor sensitivity and delayed antibody detection make them unsuitable as a diagnostic or screening tool alone.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #779520
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Clinical evaluation of SARS-CoV-2 point-of-care tests

    Robosa, Roselle s. / Sandaradura, Indy / Dwyer, Dominic e. / O’sullivan, Matthew v.N.

    2020  

    Abstract: The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on ... ...

    Abstract The aim of this study was to assess the analytic and clinical performance of four rapid lateral flow point-of-care tests (POCTs) for identifying SARS-CoV-2-specific antibodies. A retrospective study was conducted between 22 January and 30 March 2020 on 132 serum samples for SARS-CoV-2-specific antibody detection referred to a tertiary referral hospital laboratory in New South Wales. Multiple sera were tested from 20 confirmed or suspected COVID-19 patients with SARS-CoV-2-specific antibodies detected by immunofluorescence (IFA) or neutralisation, and 71 SARS-CoV-2 uninfected individuals. We measured the sensitivity and specificity for detection of SARS-CoV-2 IgM and IgG antibodies for each POCT in comparison to positive SARS-CoV-2-specific IFA and viral neutralisation, our current laboratory benchmark tests. All POCTs were found to have a low analytic sensitivity for SARS-CoV-2 antibodies, ranging from 27.3% to 58.2%, with a specificity between 88.3% and 100%, and a low clinical sensitivity from 45% to 65%, with a clinical specificity between 87.3% and 100%. All POCTs had an increased sensitivity when specimens were collected more than 14 days from onset of symptoms. The detection using POCT of SARS-CoV-2-specific antibodies after disease onset lagged behind IFA by a range of 2–9 days. POCTs promise the benefit of providing quick easy testing for SARS-CoV-2-specific antibodies. However, their poor sensitivity and delayed antibody detection make them unsuitable as a diagnostic or screening tool alone.
    Keywords COVID-19 ; Coronavirus ; covid19
    Language English
    Publishing date 2020-01-01
    Publishing country au
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia.

    Aggarwal, Anupriya / Stella, Alberto Ospina / Walker, Gregory / Akerman, Anouschka / Esneau, Camille / Milogiannakis, Vanessa / Burnett, Deborah L / McAllery, Samantha / Silva, Mariana Ruiz / Lu, Yonghui / Foster, Charles S P / Brilot, Fabienne / Pillay, Aleha / Van Hal, Sabastiaan / Mathivanan, Vennila / Fichter, Christina / Kindinger, Andrea / Hoppe, Alexandra Carey / Munier, Mee Ling /
    Amatayakul-Chantler, Supavadee / Roth, Nathan / Coppola, Germano / Symonds, Geoff P / Schofield, Peter / Jackson, Jennifer / Lenthall, Helen / Henry, Jake Y / Mazigi, Ohan / Jäck, Hans-Martin / Davenport, Miles P / Darley, David R / Matthews, Gail V / Khoury, David S / Cromer, Deborah / Goodnow, Christopher C / Christ, Daniel / Robosa, Roselle / Starck, Damien J / Bartlett, Nathan W / Rawlinson, William D / Kelleher, Anthony D / Turville, Stuart G

    Nature microbiology

    2022  Volume 7, Issue 6, Page(s) 896–908

    Abstract: Genetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using ... ...

    Abstract Genetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using primary remnant diagnostic swabs. This, combined with quarantine testing and genomics surveillance, enabled the rapid isolation and characterization of all major SARS-CoV-2 variants circulating in Australia in 2021. Our platform facilitated viral variant isolation, rapid resolution of variant fitness using nasopharyngeal swabs and ranking of evasion of neutralizing antibodies. In late 2021, variant of concern Omicron (B1.1.529) emerged. Using our platform, we detected and characterized SARS-CoV-2 VOC Omicron. We show that Omicron effectively evades neutralization antibodies and has a different entry route that is TMPRSS2-independent. Our low-cost platform is available to all and can detect all variants of SARS-CoV-2 studied so far, with the main limitation being that our platform still requires appropriate biocontainment.
    MeSH term(s) Australia ; COVID-19/diagnosis ; Humans ; Pandemics ; SARS-CoV-2/genetics
    Language English
    Publishing date 2022-05-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2058-5276
    ISSN (online) 2058-5276
    DOI 10.1038/s41564-022-01135-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: COVID-19 in Australia: our national response to the first cases of SARS-CoV-2 infection during the early biocontainment phase.

    Shaban, Ramon Z / Li, Cecilia / O'Sullivan, Matthew V N / Gerrard, John / Stuart, Rhonda L / Teh, Joanne / Gilroy, Nicole / Sorrell, Tania C / White, Elizabeth / Bag, Shopna / Hackett, Kate / Chen, Sharon C A / Kok, Jen / Dwyer, Dominic E / Iredell, Jonathan R / Maddocks, Susan / Ferguson, Patricia / Varshney, Kavita / Carter, Ian /
    Barratt, Ruth / Robertson, Mark / Baskar, Sai R / Friend, Caren / Robosa, Roselle S / Sotomayor-Castillo, Cristina / Nahidi, Shizar / Macbeth, Deborough A / Alcorn, Kylie A D / Wattiaux, Andre / Moore, Frederick / McMahon, Jamie / Naughton, William / Korman, Tony M / Catton, Mike / Kanapathipillai, Rupa / Romanes, Finn / Rowe, Emily / Catford, Jennifer / Kennedy, Brendan / Qiao, Ming / Shaw, David

    Internal medicine journal

    2020  Volume 51, Issue 1, Page(s) 42–51

    Abstract: Background: On 31 December 2019, the World Health Organization recognised clusters of pneumonia-like cases due to a novel coronavirus disease (COVID-19). COVID-19 became a pandemic 71 days later.: Aim: To report the clinical and epidemiological ... ...

    Abstract Background: On 31 December 2019, the World Health Organization recognised clusters of pneumonia-like cases due to a novel coronavirus disease (COVID-19). COVID-19 became a pandemic 71 days later.
    Aim: To report the clinical and epidemiological features, laboratory data and outcomes of the first group of 11 returned travellers with COVID-19 in Australia.
    Methods: This is a retrospective, multi-centre case series. All patients with confirmed COVID-19 infection were admitted to tertiary referral hospitals in New South Wales, Queensland, Victoria and South Australia.
    Results: The median age of the patient cohort was 42 years (interquartile range (IQR), 24-53 years) with six men and five women. Eight (72.7%) patients had returned from Wuhan, one from Shenzhen, one from Japan and one from Europe. Possible human-to-human transmission from close family contacts in gatherings overseas occurred in two cases. Symptoms on admission were fever, cough and sore throat (n = 9, 81.8%). Co-morbidities included hypertension (n = 3, 27.3%) and hypercholesterolaemia (n = 2, 18.2%). No patients developed severe acute respiratory distress nor required intensive care unit admission or mechanical ventilation. After a median hospital stay of 14.5 days (IQR, 6.75-21), all patients were discharged.
    Conclusions: This is a historical record of the first COVID-19 cases in Australia during the early biocontainment phase of the national response. These findings were invaluable for establishing early inpatient and outpatient COVID-19 models of care and informing the management of COVID-19 over time as the outbreak evolved. Future research should extend this Australian case series to examine global epidemiological variation of this novel infection.
    MeSH term(s) Adult ; Australia/epidemiology ; COVID-19/epidemiology ; COVID-19/therapy ; Female ; Humans ; Male ; Middle Aged ; Patient Discharge ; Retrospective Studies ; Tertiary Care Centers ; Young Adult
    Keywords covid19
    Language English
    Publishing date 2020-11-16
    Publishing country Australia
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2045436-3
    ISSN 1445-5994 ; 1444-0903
    ISSN (online) 1445-5994
    ISSN 1444-0903
    DOI 10.1111/imj.15105
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 792: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 424: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top